Correction to Lancet Oncol 2025; 26: 503-15

No authors listed

Published Erratum

No authors listed. Lancet Oncol. 2025 Jul.

. 2025 Jul;26(7):e349.

doi: 10.1016/S1470-2045(25)00366-3.

No abstract available

Erratum for

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.
Van Gorp T, Moore KN, Konecny GE, Leary A, García-García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Caruso G, Klasa-Mazurkiewicz D, Tromp J, Martin LP, Breuer S, Leath CA 3rd, Cibula D, Weroha SJ, Estévez-García P, O'Malley DM, Miller RE, Coffman L, Scandurra G, Berton D, Li L, Zagadailov E, Diver EJ, Trédan O, Hilpert F. Van Gorp T, et al. Lancet Oncol. 2025 Apr;26(4):503-515. doi: 10.1016/S1470-2045(25)00021-X. Lancet Oncol. 2025. PMID: 40179908 Clinical Trial.